mTORC1 hyperactivity inhibits serum deprivation-induced apoptosis via increased hexokinase II and GLUT1 expression, sustained Mcl-1 expression, and glycogen synthase kinase 3β inhibition

Molecular and Cellular Biology

Volumn 29, Issue 18, 2009, Pages 5136-5147

  Bhaskar, Prashanth T ^a   Nogueira, Veronique ^a   Patra, Krushna C ^a   Jeon, Sang Min ^a   Park, Youngkyu ^a   Robey, R Brooks ^b,c   Hay, Nissim ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE TRANSPORTER 1; GLYCOGEN SYNTHASE KINASE 3BETA; GROWTH FACTOR; HEXOKINASE; HEXOKINASE 2; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INITIATION FACTOR 4E; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN C1; PROTEIN BAD; PROTEIN KINASE B; PROTEIN MCL 1; RAPAMYCIN; TUBERIN; UNCLASSIFIED DRUG; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; MTORC1 PROTEIN, MOUSE; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PROTEIN BCL 2; SIGNAL PEPTIDE; SLC2A1 PROTEIN, MOUSE; TRANSCRIPTION FACTOR; TUBEROUS SCLEROSIS COMPLEX 1 PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVITY; ENZYME INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; ANIMAL; ANIMAL EMBRYO; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; ENZYME ACTIVATION; ENZYMOLOGY; FIBROBLAST; METABOLISM; PHOSPHORYLATION; SERUM;

RAPTORES;

ANIMALS; APOPTOSIS; BCL-ASSOCIATED DEATH PROTEIN; EMBRYO, MAMMALIAN; ENZYME ACTIVATION; EUKARYOTIC INITIATION FACTOR-4E; FIBROBLASTS; GLUCOSE TRANSPORTER TYPE 1; GLYCOGEN SYNTHASE KINASE 3; HEXOKINASE; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; SERUM; SIROLIMUS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 70249146172     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.01946-08     Document Type: Article

References (24)

1. Bhaskar, P. T., and N. Hay. 2007. The two TORCs and Akt. Dev. Cell 12:487-502.
2. Brugarolas, J. B., F. Vazquez, A. Reddy, W. R. Sellers, and W. G. Kaelin, Jr. 2003. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 4:147-158.
3. Freilinger, A., M. Rosner, G. Krupitza, M. Nishino, G. Lubec, S. J. Korsmeyer, and M. Hengstschlager. 2006. Tuberin activates the proapoptotic molecule BAD. Oncogene 25:6467-6479. (Pubitemid 44607079)
4. Ghosh, S., V. Tergaonkar, C. V. Rothlin, R. G. Correa, V. Bottero, P. Bist, I. M. Verma, and T. Hunter. 2006. Essential role of tuberous sclerosis genes TSC1 and TSC2 in NF-κB activation and cell survival. Cancer Cell 10:215-226. (Pubitemid 44311065)
5. Gottlob, K., N. Majewski, S. Kennedy, E. Kandel, R. B. Robey, and N. Hay. 2001. Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev. 15:1406-1418. (Pubitemid 32524647)
6. Graff, J. R., B. W. Konicek, T. M. Vincent, R. L. Lynch, D. Monteith, S. N. Weir, P. Schwier, A. Capen, R. L. Goode, M. S. Dowless, Y. Chen, H. Zhang, S. Sissons, K. Cox, A. M. McNulty, S. H. Parsons, T. Wang, L. Sams, S. Geeganage, L. E. Douglass, B. L. Neubauer, N. M. Dean, K. Blanchard, J. Shou, L. F. Stancato, J. H. Carter, and E. G. Marcusson. 2007. Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J. Clin. Investig. 117:2638-2648.
7. Harada, H., B. Becknell, M. Wilm, M. Mann, L. J. Huang, S. S. Taylor, J. D. Scott, and S. J. Korsmeyer. 1999. Phosphorylation and inactivation of BAD by mitochondria-anchored protein kinase A. Mol. Cell 3:413-422. (Pubitemid 29292598)
8. Inoki, K., T. Zhu, and K. L. Guan. 2003. TSC2 mediates cellular energy response to control cell growth and survival. Cell 115:577-590. (Pubitemid 37506046)
9. Kandel, E. S., and N. Hay. 1999. The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. Exp. Cell Res. 253:210-229.
10. Kennedy, S. G., E. S. Kandel, T. K. Cross, and N. Hay. 1999. Akt/Protein kinase B inhibits cell death by preventing the release of cytochrome c from mitochondria. Mol. Cell. Biol. 19:5800-5810. (Pubitemid 29339934)
11. Leung, A. K., and W. L. Robson. 2007. Tuberous sclerosis complex: a review. J. Pediatr. Health Care 21:108-114.
12. Majewski, N., V. Nogueira, P. Bhaskar, P. E. Coy, J. E. Skeen, K. Gottlob, N. S. Chandel, C. B. Thompson, R. B. Robey, and N. Hay. 2004. Hexokinase-mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak. Mol. Cell 16:819-830. (Pubitemid 39586539)
13. Majewski, N., V. Nogueira, R. B. Robey, and N. Hay. 2004. Akt inhibits apoptosis downstream of BID cleavage via a glucose-dependent mechanism involving mitochondrial hexokinases. Mol. Cell. Biol. 24:730-740. (Pubitemid 38057924)
14. Mathupala, S. P., A. Rempel, and P. L. Pedersen. 2001. Glucose catabolism in cancer cells: identification and characterization of a marked activation response of the type II hexokinase gene to hypoxic conditions. J. Biol. Chem. 276:43407-43412. (Pubitemid 37371031)
15. Maurer, U., C. Charvet, A. S. Wagman, E. Dejardin, and D. R. Green. 2006. Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol. Cell 21:749-760. (Pubitemid 43376126)
16. Pastorino, J. G., J. B. Hoek, and N. Shulga. 2005. Activation of glycogen synthase kinase 3beta disrupts the binding of hexokinase II to mitochondria by phosphorylating voltage-dependent anion channel and potentiates chemotherapy-induced cytotoxicity. Cancer Res. 65:10545-10554.
17. Rathmell, J. C., C. J. Fox, D. R. Plas, P. S. Hammerman, R. M. Cinalli, and C. B. Thompson. 2003. Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival. Mol. Cell. Biol. 23:7315-7328.
18. Robey, R. B., and N. Hay. 2006. Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt. Oncogene 25:4683-4696.
19. Shah, O. J., Z. Wang, and T. Hunter. 2004. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr. Biol. 14:1650-1656.
20. Skeen, J. E., P. T. Bhaskar, C. C. Chen, W. S. Chen, X. D. Peng, V. Nogueira, A. Hahn-Windgassen, H. Kiyokawa, and N. Hay. 2006. Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent manner. Cancer Cell 10:269-280.
21. Vander Heiden, M. G., D. R. Plas, J. C. Rathmell, C. J. Fox, M. H. Harris, and C. B. Thompson. 2001. Growth factors can influence cell growth and survival through effects on glucose metabolism. Mol. Cell. Biol. 21:5899-5912.
22. Wendel, H. G., R. L. Silva, A. Malina, J. R. Mills, H. Zhu, T. Ueda, R. Watanabe-Fukunaga, R. Fukunaga, J. Teruya-Feldstein, J. Pelletier, and S. W. Lowe. 2007. Dissecting eIF4E action in tumorigenesis. Genes Dev. 21:3232-3237.
23. Zhang, H. H., A. I. Lipovsky, C. C. Dibble, M. Sahin, and B. D. Manning. 2006. S6K1 regulates GSK3 under conditions of mTOR-dependent feedback inhibition of Akt. Mol. Cell 24:185-197.
24. Zhao, Y., B. J. Altman, J. L. Coloff, C. E. Herman, S. R. Jacobs, H. L. Wieman, J. A. Wofford, L. N. Dimascio, O. Ilkayeva, A. Kelekar, T. Reya, and J. C. Rathmell. 2007. Glycogen synthase kinase 3α and 3β mediate a glucose-sensitive antiapoptotic signaling pathway to stabilize Mcl-1. Mol. Cell. Biol. 27:4328-4339. (Pubitemid 46906557)